Detalhe da pesquisa
1.
NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts.
Blood
; 141(13): 1584-1596, 2023 03 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-36375120
2.
BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL.
Blood
; 138(19): 1843-1854, 2021 11 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34046681
3.
Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines.
Blood
; 137(2): 185-189, 2021 01 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-33259596
4.
Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib.
Blood
; 136(1): 93-105, 2020 07 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32202637
5.
A phase II study of ibrutinib and short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia.
Am J Hematol
; 95(11): E310-E313, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32808680
6.
CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy.
Clin Cancer Res
; 29(18): 3612-3621, 2023 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37227160
7.
Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting.
Blood Adv
; 7(15): 4089-4101, 2023 08 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37219524
8.
Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemia.
J Immunother Cancer
; 10(11)2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36442911
9.
Select Antitumor Cytotoxic CD8+ T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib.
Clin Cancer Res
; 27(16): 4624-4633, 2021 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33875521
10.
Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model.
J Clin Oncol
; 39(6): 576-585, 2021 02 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33026937
11.
Overcoming Acquired Epigenetic Resistance to BTK Inhibitors.
Blood Cancer Discov
; 2(6): 630-647, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34778802
12.
Risk-adapted, ofatumumab-based chemoimmunotherapy and consolidation in treatment-naïve chronic lymphocytic leukemia: a phase 2 study.
Leuk Lymphoma
; 62(8): 1816-1827, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33653216
13.
Pharmacodynamic Analysis of BTK Inhibition in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib.
Clin Cancer Res
; 26(12): 2800-2809, 2020 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32054731